Literature DB >> 17488590

New concepts on progressive multiple sclerosis.

Hans Lassmann1.   

Abstract

Multiple sclerosis is generally regarded as a putative autoimmune disease of the central nervous system in which a chronic T-cell-mediated inflammation leads to focal plaques of demyelination in the white matter of the central nervous system. This plaque-centered view of the disease, however, fails to explain clinical deterioration of the patients when they have reached the progressive stage of the disease. It was thus postulated during the past few years that besides inflammation there is a neurodegenerative component of the disease that leads to progressive and global brain damage. This article reviews recent findings that suggest a different explanation. It describes that in the early stage of acute and relapsing multiple sclerosis, focal plaques in the white matter are formed by relapsing waves of inflammation. With chronicity, however, the inflammatory response becomes trapped behind the blood-brain barrier, giving rise to slowly progressive inflammatory damage that affects the brain and spinal cord in a global sense. This is mainly reflected by extensive cortical demyelination and diffuse axonal injury within the normal-appearing white matter. This process seems to be driven by the aberrant formation of ectopic lymphatic tissue within the brain compartment.

Entities:  

Mesh:

Year:  2007        PMID: 17488590     DOI: 10.1007/s11910-007-0036-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  49 in total

1.  Immunopathology of secondary-progressive multiple sclerosis.

Authors:  J W Prineas; E E Kwon; E S Cho; L R Sharer; M H Barnett; E L Oleszak; B Hoffman; B P Morgan
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

Review 2.  Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease.

Authors:  C Bjartmar; J R Wujek; B D Trapp
Journal:  J Neurol Sci       Date:  2003-02-15       Impact factor: 3.181

3.  The distribution of plaques in the cerebrum in multiple sclerosis.

Authors:  B BROWNELL; J T HUGHES
Journal:  J Neurol Neurosurg Psychiatry       Date:  1962-11       Impact factor: 10.154

Review 4.  B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation.

Authors:  Edgar Meinl; Markus Krumbholz; Reinhard Hohlfeld
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

Review 5.  Primary progressive multiple sclerosis.

Authors:  A J Thompson; C H Polman; D H Miller; W I McDonald; B Brochet; X Filippi M Montalban; J De Sá
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

6.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

Review 7.  Lymphoid neogenesis in chronic inflammatory diseases.

Authors:  Francesca Aloisi; Ricardo Pujol-Borrell
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

8.  Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration.

Authors:  L Bø; C A Vedeler; H Nyland; B D Trapp; S J Mørk
Journal:  Mult Scler       Date:  2003-08       Impact factor: 6.312

9.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

10.  Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions.

Authors:  N Evangelou; G C DeLuca; T Owens; M M Esiri
Journal:  Brain       Date:  2004-11-17       Impact factor: 13.501

View more
  24 in total

1.  Cortical quantitative MRI parameters are related to the cognitive status in patients with relapsing-remitting multiple sclerosis.

Authors:  Alexandra van Wijnen; Franca Petrov; Michelle Maiworm; Stefan Frisch; Christian Foerch; Elke Hattingen; Helmuth Steinmetz; Johannes C Klein; Ralf Deichmann; Marlies Wagner; René-Maxime Gracien
Journal:  Eur Radiol       Date:  2019-10-10       Impact factor: 5.315

Review 2.  Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Authors:  Finn Sellebjerg; Diego Cadavid; Deborah Steiner; Luisa Maria Villar; Richard Reynolds; Daniel Mikol
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

3.  Toll-Like Receptor 2-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination.

Authors:  Stefan Esser; Larissa Göpfrich; Kai Bihler; Eugenia Kress; Stella Nyamoya; Simone C Tauber; Tim Clarner; Matthias B Stope; Thomas Pufe; Markus Kipp; Lars-Ove Brandenburg
Journal:  Mol Neurobiol       Date:  2017-12-29       Impact factor: 5.590

Review 4.  Epstein-Barr virus in multiple sclerosis.

Authors:  Bridget A Bagert
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

5.  [New therapeutic strategies for remyelination in multiple sclerosis].

Authors:  D Kremer; H-P Hartung; M Stangel; P Küry
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

6.  Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system.

Authors:  Mary Emmanouil; Era Taoufik; Vivian Tseveleki; Sotiris-Spyros Vamvakas; Theodore Tselios; Michael Karin; Hans Lassmann; Lesley Probert
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

7.  Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis.

Authors:  Marcel P Stoop; Vaibhav Singh; Lennard J Dekker; Mark K Titulaer; Christoph Stingl; Peter C Burgers; Peter A E Sillevis Smitt; Rogier Q Hintzen; Theo M Luider
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

Review 8.  Relapsing and progressive forms of multiple sclerosis: insights from pathology.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

9.  The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.

Authors:  Michael Zhong; Anneke van der Walt; Maria Pia Campagna; Jim Stankovich; Helmut Butzkueven; Vilija Jokubaitis
Journal:  Neurotherapeutics       Date:  2020-10-14       Impact factor: 7.620

10.  CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

Authors:  Jeppe Romme Christensen; Mika Komori; Marina Rode von Essen; Rikke Ratzer; Lars Börnsen; Bibi Bielekova; Finn Sellebjerg
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.